fig1
From: Tumor heterogeneity as a driver of drug resistance and its implications for personalized therapy
Figure 1. Schematic diagram of spatial and temporal heterogeneity. (A) Spatial heterogeneity. Tumors gradually differentiate into distinct subclones at the primary or at metastatic lesion sites, revealing spatial heterogeneity when sampled and analyzed at a given moment; (B) Temporal heterogeneity. Tumors not only develop distinct subclones during tumorigenesis, but these subclones also undergo progressive selection and evolution under therapeutic pressure. Sampling at different stages of tumor progression reveals temporal heterogeneity. Created in BioRender. Da, E. (2026) https://BioRender.com/8bprxj6.
